A 52-year-old man with a 10-year history of progressive bilateral conductive hearing loss is diagnosed with otosclerosis on CT temporal bone. He has failed conservative management with hearing aids. What is the drug of choice for medical management before surgical intervention?

Explanation

## Otosclerosis — Medical Management ### Pathophysiology Otosclerosis is a primary disorder of the otic capsule characterized by abnormal bone remodeling, leading to stapes fixation and progressive conductive hearing loss. The condition is autosomal dominant with incomplete penetrance and variable expression. ### Drug of Choice: Sodium Fluoride **Key Point:** Sodium fluoride is the only pharmacological agent with evidence for slowing or halting otosclerotic bone remodeling. It is indicated in patients with active otosclerosis who wish to delay or avoid surgery. ### Mechanism of Action 1. Inhibits osteoclast-mediated bone resorption 2. Promotes osteoblast-mediated bone formation 3. Stabilizes the abnormal bone remodeling cycle 4. May slow progression of hearing loss if given early ### Dosing and Efficacy - **Dose:** 20–40 mg/day (as sodium fluoride) for 2–3 years - **Efficacy:** 50–70% of patients show slowing or stabilization of hearing loss progression - **Best results:** When started in early stages (mild to moderate hearing loss) - **Monitoring:** Audiometry every 6–12 months; biochemical markers of bone turnover **High-Yield:** Sodium fluoride is most effective when otosclerosis is in the active (lytic) phase, characterized by elevated bone turnover markers and rapid hearing loss progression. Once the disease becomes sclerotic (burned-out), fluoride efficacy diminishes. ### Clinical Indications for Fluoride - Active otosclerosis with progressive hearing loss - Patient preference to delay stapedectomy - Bilateral disease with one ear severely affected - Contraindication to surgery ### Limitations and Considerations - **Efficacy variability:** Not all patients respond; ~30% show no benefit - **Long treatment duration:** Requires 2–3 years of therapy - **Side effects:** Gastrointestinal upset, nausea; must be taken on empty stomach - **Monitoring:** Serum fluoride levels, renal function, bone turnover markers - **Definitive treatment:** Stapedectomy or stapedotomy remains the gold standard for symptomatic hearing loss **Clinical Pearl:** Sodium fluoride is NOT a cure; it is a temporizing measure. Most otosclerotic patients eventually require surgery for functional hearing restoration. Fluoride is best used in patients with mild-to-moderate hearing loss who wish to delay surgery or in those with contraindications to surgical intervention. ### Comparison: Medical vs. Surgical Management | Modality | Indication | Outcome | |----------|-----------|----------| | **Sodium fluoride** | Active otosclerosis, early stages | Slows progression; 50–70% response | | **Hearing aids** | Mild-to-moderate conductive loss | Symptomatic improvement; no disease modification | | **Stapedectomy** | Symptomatic conductive loss | Definitive; 90% success rate; restores air-bone gap | | **Stapedotomy** | Preferred surgical technique | Lower risk of sensorineural loss; 90–95% success | **Warning:** Sodium fluoride does NOT reverse existing hearing loss or restore ossicular function. It only slows disease progression. Patients with significant functional hearing loss require surgical intervention for meaningful hearing restoration. [cite:Lalwani Textbook of ENT Ch 8; Glasscock & Shambaugh Surgery of the Ear Ch 12]